About Us

PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Our lead programs are focused on two of the world’s most challenging conditions – Autism Spectrum Disorder (ASD) and Fragile X-associated Tremor / Ataxia (FXTAS). There are no FDA-approved treatments for the core symptoms of ASD and no FDA-approved treatments at all for FXTAS. We are on a promising path to change that.


Michael Derby

Executive Chairman

Howard Weisman

Chief Executive Officer

Stephen D. Sheldon

Chief Financial Officer

Stefan Schwabe, MD, PhD

Chief Medical Officer

Zach Rome

Chief Operating Officer

Buzz Woods

Corporate Communications

Board of Directors

Michael Derby

Howard Weisman

Zach Rome

Dr. John F. Coelho

Karen LaRochelle

Charles J. Casamento

Advisory Board


We are continuing to pursue opportunities to license or acquire additional late-stage assets and are dedicated to collaborating with companies, academia, patient advocacy groups, and other industry stakeholders worldwide. If you are interested in a partnership with PaxMedica, please contact us at info@paxmedica.com.

For People with Autism and Their Families

If you are interested in following our progress or learning more about our clinical trials, please complete the contact form.

PaxMedica is a proud partner of:

Supporting translational research that will lead to the development of FDA-approved treatments and an improved standard of care for co-morbidities in individuals with autism.